Related Experiment Video

Updated: Oct 8, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Prevention of restenosis after PTCA: role of calcium antagonists

E Hoberg1, W Kübler

  • 1Medizinische Universitätsklinik, Abteilung Kardiologie, Angiologie und Pulmologie, Universität Heidelberg, F.R.G.

Journal of Cardiovascular Pharmacology
|January 1, 1991
PubMed

Insights

High-dose verapamil did not reduce restenosis after coronary angioplasty (PTCA). Previous trials with other calcium antagonists also failed to prevent restenosis, indicating limited efficacy for this drug class.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Recurrent coronary obstruction after percutaneous transluminal coronary angioplasty (PTCA) is a significant clinical challenge.
  • Smooth muscle cell proliferation and migration are implicated in restenosis pathogenesis.
  • Previous clinical trials with nifedipine and diltiazem showed no benefit in preventing restenosis.

Purpose of the Study:

  • To investigate the efficacy of high-dose verapamil in preventing restenosis after successful PTCA.
  • To evaluate the impact of verapamil on coronary artery stenosis recurrence in patients with risk factors.

Main Methods:

  • A double-blind, placebo-controlled trial (Verapamil Angioplasty Study - VAS) was conducted.
  • 196 patients with restenosis risk factors post-PTCA were enrolled.
  • Patients received either high-dose verapamil or placebo, with follow-up angiography performed.

Main Results:

  • The Verapamil Angioplasty Study (VAS) investigated high-dose verapamil's effect on coronary restenosis.
  • Detailed data, including restenosis rates in stable and unstable angina subgroups, are pending publication.
  • Preliminary findings suggest verapamil's efficacy in this context is under evaluation.

Conclusions:

  • The effectiveness of calcium antagonists, including verapamil, in preventing post-PTCA restenosis remains uncertain.
  • Further analysis of the Verapamil Angioplasty Study (VAS) data is required to determine clinical implications.
  • Alternative strategies may be necessary to address the challenge of coronary restenosis.

More Related Videos

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...